{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Non-Small+Cell+Lung&page=43",
    "query": {
      "condition": "Carcinoma, Non-Small Cell Lung",
      "page": 43
    },
    "page_size": 10
  },
  "pagination": {
    "page": 43,
    "page_size": 10,
    "total_count": 3680,
    "total_pages": 368,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Non-Small+Cell+Lung&page=44&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Non-Small+Cell+Lung&page=42&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T06:46:10.892Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02367781",
      "title": "A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Squamous Non-Small Cell Lung"
      ],
      "interventions": [
        {
          "name": "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 723,
      "start_date": "2015-04-16",
      "completion_date": "2021-01-18",
      "has_results": true,
      "last_update_posted_date": "2021-08-09",
      "last_synced_at": "2026-11-21T06:46:10.892Z",
      "location_count": 57,
      "location_summary": "Springdale, Arkansas • Oakland, California • Roseville, California + 52 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02367781"
    },
    {
      "nct_id": "NCT01310244",
      "title": "MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stage IV Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Belinostat, Carboplatin, Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acrotech Biopharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2010-12",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2020-01-06",
      "last_synced_at": "2026-11-21T06:46:10.892Z",
      "location_count": 4,
      "location_summary": "Huntsville, Alabama • Santa Monica, California • Boynton Beach, Florida + 1 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01310244"
    },
    {
      "nct_id": "NCT05769764",
      "title": "A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Archival tissue specimen and immunohistochemistry staining",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2022-12-19",
      "completion_date": "2023-04-06",
      "has_results": false,
      "last_update_posted_date": "2023-04-10",
      "last_synced_at": "2026-11-21T06:46:10.892Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Florence, South Carolina",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Florence",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05769764"
    },
    {
      "nct_id": "NCT05378763",
      "title": "A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "NSCLC"
      ],
      "interventions": [
        {
          "name": "Poziotinib",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spectrum Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 268,
      "start_date": "2022-05-12",
      "completion_date": "2028-12-25",
      "has_results": false,
      "last_update_posted_date": "2026-10-28",
      "last_synced_at": "2026-11-21T06:46:10.892Z",
      "location_count": 1,
      "location_summary": "Winter Haven, Florida",
      "locations": [
        {
          "city": "Winter Haven",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05378763"
    },
    {
      "nct_id": "NCT02654587",
      "title": "OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "OSE2101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "OSE Immunotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 219,
      "start_date": "2016-02-12",
      "completion_date": "2021-01-15",
      "has_results": true,
      "last_update_posted_date": "2024-02-02",
      "last_synced_at": "2026-11-21T06:46:10.892Z",
      "location_count": 10,
      "location_summary": "Burbank, California • Washington D.C., District of Columbia • Boca Raton, Florida + 7 more",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Covington",
          "state": "Louisiana"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02654587"
    },
    {
      "nct_id": "NCT02535338",
      "title": "Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Stage IV Lung Non-Small Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Erlotinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Onalespib Lactate",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2016-04-11",
      "completion_date": "2021-09-08",
      "has_results": true,
      "last_update_posted_date": "2025-03-03",
      "last_synced_at": "2026-11-21T06:46:10.892Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Los Angeles, California • Pasadena, California + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02535338"
    },
    {
      "nct_id": "NCT03041181",
      "title": "Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",
        "Adenocarcinoma of the Lung",
        "Lung Cancer",
        "Squamous Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nasser Hanna, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2017-01-27",
      "completion_date": "2019-05-23",
      "has_results": true,
      "last_update_posted_date": "2022-07-11",
      "last_synced_at": "2026-11-21T06:46:10.892Z",
      "location_count": 9,
      "location_summary": "Anderson, Indiana • Indianapolis, Indiana • Muncie, Indiana + 4 more",
      "locations": [
        {
          "city": "Anderson",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Muncie",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03041181"
    },
    {
      "nct_id": "NCT04667234",
      "title": "Expanded Access of Sotorasib",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Non Small-cell Lung Cancer",
        "Locally Advanced Unresectable NSCLC",
        "Locally Advanced Metastatic NSCLC"
      ],
      "interventions": [
        {
          "name": "AMG 510",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-11-21T06:46:10.892Z",
      "location_count": 30,
      "location_summary": "Huntsville, Alabama • Anchorage, Alaska • Chandler, Arizona + 27 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Alamosa",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04667234"
    },
    {
      "nct_id": "NCT02767804",
      "title": "eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "X-396 (ensartinib)",
          "type": "DRUG"
        },
        {
          "name": "crizotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xcovery Holdings, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 290,
      "start_date": "2016-06",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-11-21T06:46:10.892Z",
      "location_count": 4,
      "location_summary": "Tampa, Florida • Athens, Georgia • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02767804"
    },
    {
      "nct_id": "NCT05163028",
      "title": "A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Solid Tumor",
        "Cancer",
        "Cancer of Pancreas",
        "Cancer of Colon"
      ],
      "interventions": [
        {
          "name": "HBI-2376",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HUYABIO International, LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2021-12-13",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-16",
      "last_synced_at": "2026-11-21T06:46:10.892Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Encinitas, California • Fullerton, California + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "San Marcos",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05163028"
    }
  ]
}